The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
AstraZeneca announced on July 27 that its drug Ultomiris failed to meet the primary goal in a late-stage clinical trial for patients with blood vessel complications. On August 2, the Financial Times reported that the company had recently held merger discussions with Bristol Myers Squibb. These events outline a period of clinical setbacks and strategic exploration for the pharmaceutical giant.